{"nctId":"NCT00784277","briefTitle":"A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease","startDateStruct":{"date":"2008-10"},"conditions":["Joint Diseases","Arthritis","Osteoarthritis"],"count":597,"armGroups":[{"label":"001","type":"EXPERIMENTAL","interventionNames":["Drug: Tapentadol IR (CG5503)"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Drug: Tapentadol IR (CG5503)"]},{"label":"003","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oxycodone IR"]},{"label":"004","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]},{"label":"005","type":"EXPERIMENTAL","interventionNames":["Drug: Tapentadol ER (CG5503)"]},{"label":"006","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: oxycodone CR"]},{"label":"007","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo"]}],"interventions":[{"name":"oxycodone CR","otherNames":[]},{"name":"oxycodone IR","otherNames":[]},{"name":"Tapentadol ER (CG5503)","otherNames":[]},{"name":"Tapentadol IR (CG5503)","otherNames":[]},{"name":"Tapentadol IR (CG5503)","otherNames":[]},{"name":"placebo","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A clinical diagnosis of osteoarthritis of the hip or knee\n* End-stage degenerative joint disease\n* Eligibility for primary unilateral total or partial joint replacement surgery\n* Pain level moderate to severe and at such a level as to require daily doses of an opioid analgesic medication\n\nExclusion Criteria:\n\n* Has a life-long history of seizure disorder or epilepsy\n* Had any of the following within the preceding 1 year: mild or moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm\n* Had a severe traumatic brain injury within 15 years of screening (consisting of one or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post traumatic amnesia lasting for more than 24 hours)\n* Joint pain not associated with gout, fibromyalgia, rheumatoid arthritis, other autoimmune disease\n* History of alcohol or drug abuse\n* chronic hepatitis B and C or HIV, active hepatitis B and C within 3 months\n* Severely impaired renal function or moderately to severely impaired hepatic function\n* History of cancer within past 2 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"5-Day Sum of Pain Intensity Difference (SPID5)","description":"SPID5 was calculated as the weighted (weights is taken as the number of hours elapsed since the previous measurement) sum of the PID collected up to 5 days. Pain intensity (PI) score is calculated as the average PI over the past 12 hours using an 11-point (0 to 10) numerical rating scale (NRS) where \"0\" is no pain and \"10\" is pain as bad as you can imagine. The difference between baseline PI at the qualifying period and current PI is pain intensity difference (PID).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":"134.73"},{"groupId":"OG001","value":"153.1","spread":"184.07"},{"groupId":"OG002","value":"161.8","spread":"187.31"},{"groupId":"OG003","value":"218.4","spread":"208.64"}]}]}]},{"type":"PRIMARY","title":"Spontaneous Bowel Movements Per Week (SBMs/Week)","description":"The number of SBM over the 14-day IR treatment phase was determined from the Bowel Function Patient Diary and factored to enable a per week value to be used. An SBM is defined as any BM that has occurred without the use of a laxative, enema, suppository, or manual manipulation within the previous 24 hours.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":"5.16"},{"groupId":"OG001","value":"9.0","spread":"4.04"},{"groupId":"OG002","value":"8.6","spread":"4.65"},{"groupId":"OG003","value":"6.7","spread":"5.44"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":148},"commonTop":["Constipation","Nausea","Dizziness","Vomiting","Somnolence"]}}}